New pill for advanced breast cancer shows promise in early trial

NCT ID NCT03284957

Terminated Disease control Sponsor: Sanofi Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new oral drug called amcenestrant for postmenopausal women with a certain type of advanced breast cancer (ER+/HER2-). The goal was to find safe doses and see if it works alone or with other drugs. The trial was stopped early, but the results help researchers understand how to better treat this cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST CANCER

Contacts and locations

Show contact details

Locations

Fred Hutchinson Cancer Center- Site Number : 8400001

Seattle, Washington, 98109, United States
Investigational Site Number : 0560001

Leuven, 3000, Belgium
Investigational Site Number : 1240002

Toronto, Ontario, M4N 3M5, Canada
Investigational Site Number : 1240003

Vancouver, British Columbia, V5Z 1L3, Canada
Investigational Site Number : 1240004

Edmonton, Alberta, T6G 1Z2, Canada
Investigational Site Number : 2030001

Prague, 128 08, Czechia
Investigational Site Number : 2030002

Brno, 656 53, Czechia
Investigational Site Number : 2030003

Prague, 140 59, Czechia
Investigational Site Number : 2500001

Saint-Herblain, 44805, France
Investigational Site Number : 2500002

Bordeaux, 33076, France
Investigational Site Number : 2500003

Lyon, 69373, France
Investigational Site Number : 2500004

Villejuif, 94805, France
Investigational Site Number : 2500005

Lille, 59000, France
Investigational Site Number : 3800003

Milan, Milano, 20141, Italy
Investigational Site Number : 6160004

Gdynia, Pomeranian Voivodeship, 81-519, Poland
Investigational Site Number : 6200001

Lisbon, 1649-035, Portugal
Investigational Site Number : 6200002

Lisbon, 1998-018, Portugal
Investigational Site Number : 7240001

Madrid, 28041, Spain
Investigational Site Number : 7240002

Madrid, 28050, Spain
Investigational Site Number : 7240007

Madrid, 28034, Spain
Investigational Site Number : 8260002

Cardiff, Cardiff [Caerdydd Gb-crd], CF14 2TL, United Kingdom
Investigational Site Number : 8260003

Oxford, Oxfordshire, OX3 7LE, United Kingdom
Massachusetts General Hospital- Site Number : 8400002

Boston, Massachusetts, 02114, United States
Memorial Sloan Kettering Cancer Center - New York - York Avenue- Site Number : 8400003

New York, New York, 10065, United States
University of Colorado - Anschutz Medical Campus- Site Number : 8400005

Aurora, Colorado, 80045, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.